Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price rose 6.2% during mid-day trading on Tuesday . The stock traded as high as $24.73 and last traded at $24.35. Approximately 127,701 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 238,788 shares. The stock had previously closed at $22.92.
Wall Street Analysts Forecast Growth
Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They set a "buy" rating and a $34.00 price objective for the company.
Check Out Our Latest Stock Analysis on ELVN
Enliven Therapeutics Trading Up 7.8 %
The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -11.19 and a beta of 1.05. The stock has a fifty day moving average price of $17.53 and a 200-day moving average price of $14.80.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09. On average, equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.
Insider Activity at Enliven Therapeutics
In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $16.97, for a total value of $55,152.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $16.97, for a total value of $55,152.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $16.42, for a total value of $197,040.00. The disclosure for this sale can be found here. Insiders sold 252,641 shares of company stock valued at $5,588,511 in the last ninety days. Insiders own 45.80% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
A number of institutional investors have recently modified their holdings of ELVN. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Enliven Therapeutics in the 4th quarter valued at $66,000. Exchange Traded Concepts LLC raised its position in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company's stock worth $121,000 after acquiring an additional 2,208 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics during the third quarter valued at $157,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company's stock valued at $170,000 after acquiring an additional 1,029 shares during the last quarter. 95.08% of the stock is owned by institutional investors.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
